Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1977 Dec;39(12):1353–1360. doi: 10.1136/hrt.39.12.1353

Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome.

P R Reid, H L Greene, P J Varghese
PMCID: PMC483421  PMID: 603737

Abstract

Four patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome were refractory to conventional pharmacological therapy and received aprindine hydrochloride intravenously and orally. Electrophysiological studies disclosed that intravenous aprindine caused increased refractoriness and slowed conduction in the atria, atrioventricular node, ventricles, and accessory pathway. The ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli was totally abolished in all 4 patients after intravenous aprindine. Oral aprindine therapy, twice daily thereafter, provided symptomatic relief of the supraventricular tachycardia without significant side effects. Aprindine is useful in the management of supraventricular tachycardia associated with Wolff-Parkinson-White and may offer significant advantages over currently available therapy.

Full text

PDF
1353

Images in this article

1355Image
on p.1355
1356Image
on p.1356
1357Image
on p.1357
1357Image
on p.1357
1358Image
on p.1358

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dreifus L. S., Nichols H., Morse D., Watanabe Y., Truex R. Control of recurrent tachycardia of Wolff-Parkinson-White syndrome by surgical ligature of the A-V bundle. Circulation. 1968 Dec;38(6):1030–1036. doi: 10.1161/01.cir.38.6.1030. [DOI] [PubMed] [Google Scholar]
  2. Elharrar V., Foster P. R., Zipes D. P. Effects of aprindine HCL on cardiac tissues. J Pharmacol Exp Ther. 1975 Nov;195(2):201–205. [PubMed] [Google Scholar]
  3. Fasola A. F., Carmichael R. The pharmacology and clinical evaluation of aprindine a new antiarrhythmic agent. Acta Cardiol. 1974;Suppl 18:317–333. [PubMed] [Google Scholar]
  4. Hagemeijer F., Janse C., Hugenholtz P. G. Efficacité antiarythmique de l'aprindine à la phase aiguë de l'infarctus du myocarde. Acta Cardiol. 1974;Suppl 18:409–421. [PubMed] [Google Scholar]
  5. Kesteloot H. General aspects of anti-arrhythmic treatment with aprindine. Acta Cardiol. 1974;Suppl 18:303–316. [PubMed] [Google Scholar]
  6. Murphy P. J. Metabolic pathways of aprindine. Acta Cardiol. 1974;Suppl 18:131–142. [PubMed] [Google Scholar]
  7. Palma-Gamiz J. L., Boedo C., Lopez-Pujol F. J., de Uria J. S. Etude clinique d'un nouvel anti-arythmique: aprindine. Acta Cardiol. 1974;Suppl 18:361–368. [PubMed] [Google Scholar]
  8. Rosenbaum M. B., Chiale P. A., Ryba D., Elizari M. V. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974 Aug;34(2):215–223. doi: 10.1016/0002-9149(74)90200-8. [DOI] [PubMed] [Google Scholar]
  9. Scherlag B. J., Lau S. H., Helfant R. H., Berkowitz W. D., Stein E., Damato A. N. Catheter technique for recording His bundle activity in man. Circulation. 1969 Jan;39(1):13–18. doi: 10.1161/01.cir.39.1.13. [DOI] [PubMed] [Google Scholar]
  10. Steinberg M. I., Greenspan K. Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine. Cardiovasc Res. 1976 Mar;10(2):236–244. doi: 10.1093/cvr/10.2.236. [DOI] [PubMed] [Google Scholar]
  11. Svenson R. H., Gallagher J. J., Sealy W. C., Wallace A. G. An electrophysiologic approach to the surgical treatment of the Wolff-Parkinson-White syndrome. Report of two cases utilizing catheter recording and epicardial mapping techniques. Circulation. 1974 May;49(5):799–804. doi: 10.1161/01.cir.49.5.799. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES